Breast neoplasms Trials in Jinan, China
Conditions / Breast neoplasms / Jinan, China
Research into Breast neoplasms spans multiple therapeutic approaches and trial phases.
11 total trials for this combination
Showing top 10 of 11 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06926868 | A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) | RECRUITING | — |
| NCT04975308 | A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT07060807 | A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) | RECRUITING | — |
| NCT04895358 | Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT05346224 | A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT03500380 | A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases | UNKNOWN | PHASE2/PHASE3 |
| NCT05514054 | A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT06966700 | A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) | RECRUITING | — |
| NCT01125566 | LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment | COMPLETED | PHASE3 |
| NCT06966700 | A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) | RECRUITING | — |